IMD business school for management and leadership courses
AstraZeneca leverages AI to enhance each stage of drug development, from discovery to manufacturing. In drug discovery, AI-powered knowledge graphs integrate vast networks of data on genes, proteins, diseases, and drugs, helping scientists identify connections and generate hypotheses for new treatments. The company also uses language models like ChatGPT and ClinicalBERT to analyze scientific literature and clinical data, enabling rapid repurposing of existing medicines.
For clinical trials, AstraZeneca applies machine learning techniques, including convolutional neural networks (CNNs) and generative adversarial networks (GANs), to optimize trial design. By creating virtual control groups using past clinical data, they can reduce reliance on placebo groups, improving trial efficiency and patient outcomes. In manufacturing, AstraZeneca’s smart factories utilize AI for real-time process optimization. Digital lighthouse sites in China and Sweden serve as testing grounds for AI-driven solutions that synchronize production processes and enhance operational efficiency. These sites employ advanced analytics and data visualization to improve safety, quality, and efficiency.
2024 AI-related highlights
- Collaborates with MDKKU and depa Thailand to use AI for early heart failure and lung cancer detection. (Jun 2024)
- GSK and AstraZeneca utilize AI to repurpose drugs, improve research efficiency, and enhance treatment outcomes for complex diseases. (Aug 2024)
- Partners with Immunai for AI-driven cancer drug trials, investing $18m to enhance efficiency. (Sept 2024)
- AstraZeneca’s MILTON AI tool predicts over 1,000 diseases before diagnosis, enhancing early intervention and personalized treatments. (Sept 2024)
- Owkin partners with AstraZeneca to create an AI tool for gBRCA prescreening in breast cancer patients. (Oct 2024)